Zepbound vs. Foundayo: Results, Side Effects, and Uses
Compare Zepbound and Foundayo, including weekly injection versus daily pill, trial weight loss, FDA-approved uses, side effects, and interactions.
WEIGHT MANAGEMENTTREATMENT OPTIONS
Sarina Helton, MSN, APRN, FNP-C, CAE-OM Founder, Optima Vida Healthcare
9/12/20268 min read
Zepbound vs. Foundayo: Weekly Injection or Daily Weight-Loss Pill?
Zepbound and Foundayo are FDA-approved medications for chronic weight management in eligible adults. Both affect appetite, food intake, blood glucose, and gastric emptying, but they are different drugs with different mechanisms, administration schedules, labeled indications, interaction profiles, and clinical-trial results.
Zepbound contains tirzepatide and is injected once weekly. Foundayo contains orforglipron and is taken as a tablet once daily. Neither medication is automatically the better option for every patient.
This article provides a general comparison. It does not determine which medication, dose, or transition plan is appropriate for an individual.
The Main Difference
Zepbound is a peptide medication that activates both GIP and GLP-1 receptors. Foundayo is a nonpeptide small molecule that activates the GLP-1 receptor.
Both pathways influence appetite and food intake. Tirzepatide’s dual-receptor activity is one important pharmacologic difference, but receptor count alone does not predict an individual response. Medication exposure, dose, adherence, adverse effects, medical history, and individual biology also matter.
How Each Medication Is Taken
Zepbound
Zepbound is administered by subcutaneous injection once weekly. FDA-approved presentations include single-dose pens, single-dose vials, multidose vials, and single-patient-use KwikPens. The device and training requirements depend on the exact product dispensed.
The labeled strengths range from 2.5 mg to 15 mg. For chronic weight reduction, the labeled maintenance strengths are 5 mg, 10 mg, and 15 mg once weekly. Treatment response and tolerability guide maintenance selection.
Foundayo
Foundayo is an oral tablet taken once daily. It does not require fasting, a limited amount of water, or a waiting period before food, beverages, or other oral medication.
The labeled strengths range from 0.8 mg to 17.2 mg, with gradual escalation described in the prescribing information. Dose selection is based on response, tolerability, and drug interactions.
Milligram amounts cannot be compared across the two medications. A larger number of milligrams does not make one drug stronger than another.
More information about the oral option is available in Foundayo for Weight Loss.
Approved Uses
Both medications are approved, together with reduced-calorie nutrition and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight plus at least one weight-related condition.
Zepbound also has an FDA-approved indication for moderate to severe obstructive sleep apnea in adults with obesity. Foundayo does not currently have that indication. Learn more in Zepbound and Obstructive Sleep Apnea.
Neither Zepbound nor Foundayo is a diabetes-labeled brand. Mounjaro contains tirzepatide and is approved for type 2 diabetes. Both weight-management medications can lower glucose, so diabetes status and concurrent glucose-lowering medications remain clinically relevant.
Neither medication is currently approved for pediatric weight management.
Which Produced More Weight Loss in Clinical Trials?
Zepbound produced greater average weight reduction in its pivotal obesity trial program than Foundayo produced in its separate program.
In SURMOUNT-1, adults without type 2 diabetes receiving tirzepatide had mean weight reductions of approximately 15.0% with 5 mg, 19.5% with 10 mg, and 20.9% with 15 mg at 72 weeks, compared with 3.1% with placebo.
In the Foundayo Trial 1, adults without type 2 diabetes had mean weight reductions of approximately 7.4% with 5.5 mg, 8.3% with 9 mg, and 11.1% with 17.2 mg at 72 weeks, compared with 2.1% with placebo, using the FDA label’s intent-to-treat analysis.
These numbers are not from a head-to-head trial. The studies differed in participants, medication structure, discontinuation, statistical methods, and other design features. Cross-trial results describe group averages; they cannot predict exactly how an individual will respond.
The available evidence supports saying that Zepbound produced greater average weight loss in its clinical program—not that it will be more effective or more appropriate for every person.
Side Effects
The adverse-effect profiles overlap because both medications involve GLP-1 activity. Common effects include:
Nausea
Diarrhea
Vomiting
Constipation
Abdominal discomfort
Indigestion or reflux
Reduced appetite
Fatigue
Hair loss or shedding reported during substantial weight loss
Zepbound can also cause injection-site reactions. Gastrointestinal effects are often more common during dose escalation. Related education is available in Most Common GLP-1 Side Effects
The absence of adverse effects does not mean a medication is ineffective. Severe nausea or vomiting does not indicate superior treatment response.
Important Warnings and Precautions
Both medications have warnings involving severe gastrointestinal reactions, acute kidney injury related to volume depletion, gallbladder disease, pancreatitis, serious hypersensitivity reactions, and hypoglycemia when combined with insulin or an insulin secretagogue.
Both delay gastric emptying and may affect the absorption of oral medication. This also matters before procedures involving general anesthesia or deep sedation because pulmonary aspiration has been reported with GLP-1–based therapies.
Neither medication is recommended in patients with severe gastroparesis.
Severe or persistent abdominal pain, repeated vomiting, marked dehydration, facial or throat swelling, difficulty breathing, or abdominal swelling with inability to pass stool or gas are not routine appetite effects. These symptom patterns require urgent or emergency evaluation.
Thyroid C-Cell Tumor Warning
Zepbound and Foundayo carry boxed warnings involving the potential risk of thyroid C-cell tumors. Both are contraindicated with:
A personal or family history of medullary thyroid carcinoma
Multiple endocrine neoplasia syndrome type 2
A known serious hypersensitivity reaction to the active ingredient or product excipients
The scientific basis of the nonclinical data differs between the products, but both labels retain the warning and contraindications. Routine calcitonin measurement or thyroid ultrasound is described as being of uncertain value for early detection of medullary thyroid carcinoma. Read The Thyroid C-Cell Tumor Warning and GLP-1 Medications for additional context.
Drug Interactions
Foundayo Has More Metabolism-Based Interactions
Orforglipron is affected by CYP3A4 and drug-transporter pathways. The current Foundayo label limits the maximum dose when used with a strong CYP3A4 inhibitor, advises against strong inhibitors that also inhibit OATP1B, and advises against strong CYP3A4 inducers.
Examples of potentially relevant drugs include clarithromycin, ritonavir, carbamazepine, phenytoin, phenobarbital, rifampin, and St. John’s wort. Foundayo also has a labeled interaction affecting simvastatin exposure.
This interaction profile makes a complete medication and supplement review particularly important. Learn about CYP3A4 inhibitors
Zepbound Does Not Have the Same CYP3A4 Restrictions
Tirzepatide is not managed through the same CYP3A4 dose restrictions. Zepbound still delays gastric emptying and can affect absorption of oral medications, especially products that require precise concentrations or rapid gastrointestinal absorption.
Both medications can increase hypoglycemia risk when combined with insulin or a sulfonylurea.
Oral Hormonal Contraceptives
Both labels include temporary precautions involving oral hormonal contraception because delayed gastric emptying may reduce oral contraceptive effectiveness.
The Zepbound label describes a nonoral contraceptive method or added barrier method for four weeks after initiation and four weeks after each dose escalation. The Foundayo label uses 30-day periods after initiation and each escalation. Nonoral hormonal contraceptives are not expected to be affected in the same way.
This is medication-specific reproductive information, not a universal contraceptive plan. Pregnancy prevention and medication use require individualized review.
Pregnancy
Neither medication is used for weight reduction during pregnancy. Both labels state that the medication may cause fetal harm and address discontinuation when pregnancy is recognized.
Pregnancy planning requires product-specific review because drug clearance and labeling differ. General comparison information cannot determine an individual stop date or contraception plan.
Can Zepbound and Foundayo Be Used Together?
No approved evidence supports combining them. Zepbound labeling states that coadministration with another tirzepatide-containing product or a GLP-1 receptor agonist is not recommended. Foundayo labeling likewise does not support combination with another GLP-1–based weight-management medication.
Overlapping therapy could intensify gastrointestinal effects, dehydration, kidney injury, and hypoglycemia risk with certain diabetes medications. See Can GLP-1 Medications Be Combined?.
Switching Between Zepbound and Foundayo
There is no FDA-approved milligram-to-milligram conversion between tirzepatide and orforglipron. They have different pharmacology, half-lives, dosing schedules, and escalation requirements.
A clinician may evaluate a switch because of administration preference, tolerability, adherence, availability, coverage, cost, or treatment response. The timing and starting strength cannot be determined by comparing the numbers on the labels, and the medications should not be overlapped without a specific clinical plan.
Practical Differences That May Influence Selection
Zepbound may be more practical when weekly dosing is preferred, greater average trial efficacy is a priority, or its obstructive-sleep-apnea indication is clinically relevant.
Foundayo may be more practical when avoiding injections is a priority and a daily tablet is easier to use consistently. Its CYP3A4 transporter and simvastatin interactions can be limiting in some medication regimens.
Insurance coverage, formulary status, self-pay cost, pharmacy availability, prior treatment, gastrointestinal history, reproductive considerations, and concurrent medications can all change the risk-benefit assessment. The broader decision process is explained in How Are Anti-Obesity Medications Selected?.
Frequently Asked Questions
Is Foundayo the Oral Version of Zepbound?
No. Zepbound contains tirzepatide and activates GIP and GLP-1 receptors. Foundayo contains orforglipron and activates the GLP-1 receptor. They are different medications rather than injectable and oral versions of the same drug.
Which Produced More Average Weight Loss in Trials?
Zepbound produced greater average weight reduction in its separate pivotal obesity trial program. Because there has not been an adequate head-to-head obesity trial, the percentages cannot establish how the two drugs would compare in the same population.
Does Foundayo Require Fasting?
No. The FDA label states that Foundayo may be taken with or without food. This differs from the fasting requirements for oral Wegovy.
Which Medication Is Approved for Obstructive Sleep Apnea?
Zepbound is approved for moderate-to-severe obstructive sleep apnea in adults with obesity. Foundayo does not currently have that indication.
Can Zepbound and Foundayo Be Combined?
Their FDA labels do not recommend combining either medication with another GLP-1 receptor agonist. There is no approved evidence supporting Zepbound and Foundayo combination therapy.
The Bottom Line
Zepbound and Foundayo are both FDA-approved for long-term weight management in eligible adults, but they are not interchangeable.
Zepbound is once-weekly injectable tirzepatide and activates GIP and GLP-1 receptors.
Foundayo is once-daily oral orforglipron and activates the GLP-1 receptor.
Zepbound produced greater average weight reduction in its separate obesity trial program.
Foundayo avoids injections and has no fasting or water restrictions.
Zepbound has an additional obstructive-sleep-apnea indication.
Foundayo has more CYP3A4 and transporter-related interactions.
Both have overlapping gastrointestinal and serious safety warnings.
Both have temporary precautions involving oral hormonal contraceptives.
They should not be combined, and there is no direct dose conversion.
The clinically appropriate choice depends on medical history, current medications, treatment response, tolerability, administration preference, reproductive considerations, coverage, and long-term goals.
Written by and clinically reviewed for accuracy by:
Sarina Helton, MSN, APRN, FNP-C, CAE-OM
Sarina Helton, MSN, APRN, FNP-C, CAE-OM, is a board-certified family nurse practitioner and founder of Optima Vida Healthcare. Her clinical focus includes obesity medicine, medical weight management, metabolic health, hormone-related concerns, sexual health, hair loss, and evidence-based telehealth care.
Last medically reviewed: September 3rd, 2026
Ready to Explore Medical Weight Management?
Optima Vida Healthcare provides individualized weight-management evaluations with ongoing monitoring and support. Treatment may include a GLP-1 or another weight-management medication when clinically appropriate.
Start Your Weight-Management Evaluation →
Visit www.ovhmed.com for more information.
Prescription medication is not guaranteed and is prescribed only when clinically appropriate after evaluation by a licensed healthcare professional.
Learn about OVH’s medical weight-loss clinic in Owasso and statewide Oklahoma telehealth care.
Medical Disclaimer
This article is provided for general educational purposes only. It is not individualized medical or pharmaceutical advice and does not replace diagnosis, treatment, medication instructions, or care from a qualified healthcare professional. FDA labeling, coverage, devices, and availability may change.
Sources
Jastreboff et al.: Tirzepatide Once Weekly for the Treatment of Obesity
Malhotra et al.: Tirzepatide for Obstructive Sleep Apnea and Obesity
U.S. Food and Drug Administration. Zepbound Prescribing Information. Revised February 2026. FDA label
U.S. Food and Drug Administration. Foundayo Prescribing Information. Revised July 2026. FDA label
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:205–216. Study
Wharton S, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine. 2025;393:1796–1806. Study
Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. New England Journal of Medicine. 2024;391:1193–1205. Study
Zepbound vs. Foundayo: Results, Side Effects, and Uses
Compare Zepbound and Foundayo, including weekly injection versus daily pill, trial weight loss, FDA-approved uses, side effects, and interactions.
/zepbound-vs-foundayo
Zepbound vs Foundayo
tirzepatide vs orforglipron, Foundayo weight loss, Zepbound weight loss, oral GLP-1 pill, weekly weight-loss injection
Zepbound is a weekly GIP/GLP-1 injection, while Foundayo is a daily oral GLP-1 pill. Compare their trial results, indications, side effects, and interactions.
Zepbound injection pen and Foundayo oral medication comparison
Article with FAQ Page markup
Contact
Optima Vida Healthcare, LLC
Telehealth medical services
support@ovhmed.com
© 2026 Optima Vida Healthcare, LLC. All rights reserved.